Werewolf Therapeutics, Inc. (HOWL) News
Filter HOWL News Items
HOWL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HOWL News Highlights
- For HOWL, its 30 day story count is now at 2.
- Over the past 7 days, the trend for HOWL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest HOWL News From Around the Web
Below are the latest news stories about WEREWOLF THERAPEUTICS INC that investors may wish to consider to help them evaluate HOWL as an investment opportunity.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The IndustryWerewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shareholders would be excited to see that the share price has had a great... |
Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the mostKey Insights Werewolf Therapeutics' significant private equity firms ownership suggests that the key decisions are... |
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceWATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside c |
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – – Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide therapeutic index supportive of continued dose escalation – – Additional interim WTX-124 monotherapy data and recommended dose for expansion expected in the first half of 2024 – – Announcing the addition of |
CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 EarningsCarvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report. |
Delta Air Lines Layoffs 2023: What to Know About the Latest DAL Job CutsDelta Air Lines layoffs have the air travel company announcing minor adjustments to its corporate and management positions. |
Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?Werewolf Therapeutics stock is taking off with heavy trading of HOWL shares after posting preliminary data from a clinical trial. |
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingPreliminary data on WTX-124 provide compelling early evidence of dose-dependent biomarker and antitumor activity in patients with advanced or metastatic solid tumors relapsed or refractory to standard of care therapy, including two patients with ongoing unconfirmed partial responses (uPR) in the highest dose tested to date, cohort 4 (12 mg) - Safety data indicate WTX-124 is generally well-tolerated through cohort 4 with no dose limiting toxicities and no indication of vascular leak syndrome (VLS |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic on Thursday and we're checking out all of the biggest ones worth watching this morning! |
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingInterim, first-in-human clinical results from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 including safety and preliminary antitumor activity to be described in poster presentation.Additional posters representing an expansive body of data demonstrating the potential of Werewolf’s PREDATOR™ platform and INDUKINE™ product candidates will also be presented.Company to host conference call and webcast to review WTX-124 initial clinical results November 3, 2023, |